Audit & Risk Assurance Committee Meeting

Bwrdd Iechyd Prifysgol Hywel Dda University Health Board

Agenda

Date	13 August 2026
Time	09:30 - 12:00 British Summer Time (UTC+01:00)
Location	Microsoft Teams Meeting; HDD Picton - Dolau Cothi
Title	Audit & Risk Assurance Committee Meeting

---

1 - 1 Introductions

09:30,

1.1 - Apologies *For information*

09:30, Rhodri Evans (Hywel Dda UHB - Independent Member)

1.2 - Declaration of Interests *For information*

09:30, All

HDdUHB Register of Board Members Interests 2026-27

2 - Governance

09:30,

2.1 - Minutes of the Meetings held on 7 May and 23 June 2026 *For approval*

09:30, Rhodri Evans (Hywel Dda UHB - Independent Member)

2.2 - Table of Actions *For assurance*

09:30, Rhodri Evans (Hywel Dda UHB - Independent Member)

2.3 - Matters Arising not on Agenda *For discussion*

09:35, Rhodri Evans (Hywel Dda UHB - Independent Member)

2.4 - Escalation Status Update Report *For assurance*

09:35, Philip Kloer (Hywel Dda UHB - Chief Executive), Lee Davies (Hywel Dda UHB - Executive Director of Strategy and Planning), Shaun Ayres (Hywel Dda UHB - Director of Delivery)

3 - Audit Wales

09:50,

3.1 - Audit Wales Update Report *For assurance*

09:50, Anne Beegan, Urvisha Perez

3.2 - Review of Cancer Services *For assurance*

09:55, Anne Beegan, Urvisha Perez

DEFERRED to 15 October 2026 meeting

3.3 - Deep Dive Review of the Arrangements to Manage Estates *For assurance*

09:55, Anne Beegan, Urvisha Perez

DEFERRED to 15 October 2026 meeting

4 - Financial Focus

09:55,

4.1 - Financial Assurance Report *For assurance*

09:55, Huw Thomas (Hywel Dda UHB - Director of Finance)

4.2 - Counter Fraud Update *For information*

10:00, Benjamin Rees (Hywel Dda UHB - Local Counter Fraud Specialist)

5 - NWSSP – Audit and Assurance Services - Internal Audit

10:05,

5.1 - Internal Audit Plan Progress Report

For assurance

10:05, James Johns (NWSSP - Internal Audit)

5.2 - Correspondence Regarding Audit Participation and Implementation of Recommendations

For discussion

10:15, Rhodri Evans (Hywel Dda UHB - Independent Member), Eleanor Marks (Hywel Dda UHB - HDUHB Vice Chair), Joanne Wilson (Hywel Dda UHB - Director of Corporate Governance/Board Secretary)

5.3 - Capital Equipping (Limited Assurance)

For assurance

10:25, James Johns (NWSSP - Internal Audit), Lee Davies (Hywel Dda UHB - Executive Director of Strategy and Planning)

5.4 - Progress Update on Major Infrastructure Investment Programme Internal Audit

For assurance

10:45, Lee Davies (Hywel Dda UHB - Executive Director of Strategy and Planning), Rob Elliott (Hywel Dda UHB - Programme Director Major Infrastructure Projects)

5.5 - BREAK

11:00,

5.6 - Progress Update on Human Tissue Authority Internal Audit

For assurance

11:10, James Severs (Hywel Dda UHB - Executive Director of Allied Health Professions and Health Science), Jonathan Arthur (Hywel Dda UHB - Deputy Director of Health Sciences), Craig Baker (Hywel Dda UHB - Cellular Pathology Service Manager)

6 - Assurance and Risk

11:25,

6.1 - Scrutiny of Outstanding Improvement Plans - Update on Status of Risks and Audits: Community and Integrated Medicine

For assurance

11:25, Andrew Carruthers (Hywel Dda UHB - Chief Operating Officer), Peter Skitt (Hywel Dda UHB - Clinical Care Group Service Director - Community & Integrated Medicine), Anna Chiffi (Hywel Dda UHB - Assistant Director of Nursing, Patient Safety, Quality)

6.2 - Risk Assurance Report

For assurance

11:45, Joanne Wilson (Hywel Dda UHB - Director of Corporate Governance/Board Secretary)

7 - For Information

11:55,

7.1 - ARAC Workplan 2026/27

For information

11:55,

8 - Any Other Business

11:55,

9 - Review of Meeting

12:00,

9.1 - Matters and Risks for Escalation to the Board

For discussion

12:00,

10 - Date and Time of Next Meeting

12:00,
9.30am, 15 October 2026

|| - In-Committee Session

12:00,
In accordance with the Committee’s Terms of Reference, which permit the Committee to operate an in-committee function for the consideration of sensitive and/or confidential information, the next part of the meeting will be held in private session. Attendance will be restricted to Committee Members and those individuals (or their nominated deputies) identified in the Terms of Reference.

This session will consider the following items:
1. Counter Fraud Investigations

A summary of matters considered will be reported to the next appropriate Committee meeting.